European Study on Prediction of Outcome in Patients With Idiopathic Normal Pressure Hydrocephalus

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2009 by International Neuroscience Institute Hannover.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Sahlgrenska University Hospital, Sweden
Department of Neurology and Neurosurgery,Westeinde Hospital, Den Haag
Uppsala University Hospital
University of Copenhagen
Unfallkrankenhaus Berlin
Saarland University
University of Padua
Masaryk University
Neurosurgical Department, University of Budapest, Hungary
Hospital Universitari de Bellvitge
Hospital General Universitario Gregorio Marañon
Neurosurgical Department, Clinique St. Jaen, Brussels, Belgium
Information provided by:
International Neuroscience Institute Hannover
ClinicalTrials.gov Identifier:
NCT00874198
First received: April 1, 2009
Last updated: April 2, 2009
Last verified: April 2009
  Purpose

The purpose of the study is to determine the predictive values and prognostic accuracies of CSF dynamic measures, the TAP -TEST (high-volume cerebrospinal fluid withdrawal), resistance to CSF outflow and compliance in the prediction of shunt-treatment outcome in patients with idiopathic normal pressure hydrocephalus.


Condition Intervention
Normal Pressure Hydrocephalus
Procedure: Ventriculo-peritoneal Shunt

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Diagnostic
Official Title: European Multicenter Study on the Prediction of Outcome in Patients With Idiopathic Normal Pressure Hydrocephalus

Resource links provided by NLM:


Further study details as provided by International Neuroscience Institute Hannover:

Primary Outcome Measures:
  • Modified Rankin Scale [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Neuropsychological measures (Stroop test, REy-auditory verbal learing test, PEG-BOARD TEST), Balance -score, Incontinence-score, Gait-score, Walking-score [ Time Frame: three and 12 months ] [ Designated as safety issue: No ]
  • Balance -score [ Time Frame: three and 12 months ] [ Designated as safety issue: No ]
  • Incontinence-score [ Time Frame: three and 12 months ] [ Designated as safety issue: No ]
  • Gait-score [ Time Frame: three and 12 months ] [ Designated as safety issue: No ]
  • Walking-score [ Time Frame: three and 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 156
Study Start Date: October 2004
Estimated Study Completion Date: June 2009
Primary Completion Date: March 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Procedure: Ventriculo-peritoneal Shunt
    Surgical implantation of a ventriculo-peritoneal cerebrospinal fluid shunt with an adjustable valve system using the Codman-Hakim programmable valve system [pressure settings: 30 - 200 mmH20]
    Other Name: see above
  Hide Detailed Description

Detailed Description:

Study background:

The selection of patients with idiopathic normal pressure hydrocephalus (INPH) for shunting remains difficult. The upcoming guidelines for the diagnosis and management of INPH state that there is no accepted standard for the clinical presentation, the results of imaging and the various tests that provide information on CSF dynamics 1. Hebb and Cusiamo could not find a single test that reliably predicts outcome after shunting in their systematic review of INPH 2. To properly evaluate the predictive value of diagnostic tests for the outcome of shunting all patients should receive a shunt irrespective of the test results. Only a few studies set up to examine the diagnostic reliability of tests of CSF dynamics fulfilled this condition. The common finding of these studies was that the predictive value of a positive test was high but the negative predictive values were disappointingly low.

In the Dutch Normal Pressure Hydrocephalus Study, containing 101 patients, the positive and negative predictive values of lumbar constant flow infusion were 92% and 34% for an Rout of 18 mmHg/ml/min and 100% and 27% for an Rout of 24 3. External lumbar CSF drainage for 4 days resulted in positive and negative predictive values of 87% and 36% 4. The predictive value of the cerebrospinal fluid tap test reported by Wikkelso et al in 1986 was 100% for a positive and 45% for a negative test 5 Another parameter of CSF dynamics is elastance that can be expressed by the pressure volume-index (PVI). In a group of 30 patients with NPH high elastance, i.e low PVI was the best predictor of a marked and rapid reduction of ventricular size after shunting 6.

One of the major issues is whether the false negative tests mostly occur in the same population. In these patients the INPH might be caused not so much by a CSF circulation disorder but by parenchymal disease. From our clinical experience we think that different patients have false negative tests, we frequently encounter cases with a positive tap test and a negative infusion test or the reverse. This is also shown in a study by Kahlon et al. who performed an infusion test and a tap test in 68 patients suspected of NPH. Both tests agreed in only 45% and they were both negative in 31% of patients 7.

An important drawback of all INPH studies so far is the rather limited number of patients and, the "mixing" of idiopathic NPH patients (primary NPH) with those of known cause (secondary NPH) such as trauma, subarachnoid hemorrhage and stroke.INPH is considered a multfactorial condition with a disturbance of CSF circulation as well as parenchymal abnormalities in a vulnerable population with much comorbidity. Because of the many outcome variables a study on the prediction of outcome needs large numbers of INPH patients. With a few exceptions, previous studies on CSF dynamics in INPH were conducted in single high quality institutions. We also have to demonstrate that the same or even better results can be obtained with international cooperation providing higher patients numbers. Therefore we intend to conduct a large European multicentre study on INPH including at least 200 patients. All these patients will receive the same shunt system and will be followed-up by a standardized protocol using primary and secondary NPH outcome measures. Because of the continuing controversy with respect to the appropriate shunt opening pressure and the many problems of over- and underdrainage after insertion of the shunt, we chose the Codman Hakim programmable valve 8.

STUDY AIMS

To determine primarily the sensitivity, specificity, positive- and negative predictive value of resistance to outflow of CSF (Rout) and the CSF-Tap-Test for prediction of the effect of shunt surgery in patients with idiopathic NPH (INPH) by a prospective "blinded" confirmative study.

Secondarily the predictive value of elastance and CSF biochemical markers will be evaluated in the same population.

Further, the predictive value of other tests as rCBF and vascular reserve capacity (PET or SPECT), MR investigations (i.e. fMRI, MRS and/or diffusion tensor imaging etc.), continuous CSF drainage, B-wave analyses and other investigations can be evaluated by cooperation between individual centres.

General study design:

A prospective "blinded" confirmative study of at least 200 consecutively included patients with INPH fulfilling the clinical and radiological inclusion and exclusion criteria. Patients will be included during a period of 2 years by 20 or more centres that will enrol at least 5 patients per year each. All patients in the study will receive a ventriculo-peritoneal shunt, using the Codman Programmable valve.

After inclusion but prior to surgery 4 obligatory tests will be performed. We will measure the resistance to outflow of CSF (Rout) and the intracranial elastance, a CSF-Tap-Test will be carried out and CSF biochemical markers are determined. The caretakers are blinded for these results. Rout and the results of the tap test are the primary investigations.

Optional tests as rCBF and vascular reserve capacity (PET or SPECT), MR investigations (i.e. fMRI, MRS and/or diffusion tensor imaging ), continuous CSF drainage and B-wave analyses will also be performed prior to surgery. The number of patients included in a study of an optional test should be at least 30 in order to qualify for recording of the data in the database.

The patients are evaluated by a battery consisting of a handicap scale (modified Rankin scale) and 7 tests that measure gait, cognition and bladder function, before and 3 and 12 months after surgery or establishment of a working shunt. The patients are also checked one month after surgery to secure shunt efficacy.

The changes in clinical signs and disability after surgery are correlated to the results of the obligatory and optional tests. The primary outcome measures are the differences between the pre-operative and 12 months scores in the Rankin Scale and the composite NPH scale. These will be correlated with the results of the two primary investigations, resistance to CSF outflow (mmHg/ml/min) and CSF Tap Test (% change).

Patients data will be stored electronically in a web-based central data base using a special data security system for data transfer. Access to the database will be provided through an official homepage protected by a certified username/password based authenticity mechanism.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis (neurological and radiological criteria) of idiopathic normal pressure hydrocephalus

Typical INPH

Clinical criteria:

  • Gradually developed gait disturbance of both legs, unexplained by other conditions. Disturbance of tandem walking, multi-step turning, small steps and wide base must be present at least.
  • MMSE score 21-30 without aphasia, apraxia and agnosia
  • Bladder instability and postural instability may be present.

Radiological criteria (MRI):

  • Symmetrical communicating quadri-ventricular enlargement without cortical infarcts or other clinically relevant parenchymal lesions but lacunar infarcts of less than 1 cc may be present
  • Evans index > 0.30 and temporal horns and third ventricle relatively enlarged.
  • Mild cortical atrophy and mild leuco-araiosis may be present.

Questionable NPH

Clinical criteria:

  • Any gait disturbance of both legs that does not fulfill the criteria of typical INPH, but is compatible with INPH.
  • MMSE score < 21
  • Bladder instability and postural instability may be present.

Radiological criteria (MRI):

  • Symmetrical communicating quadri-ventricular enlargement without major parenchymal lesions. Single cortical infarcts and lacunar infarcts may be present.
  • Evans index > 0.30.
  • Moderate cortical atrophy and moderate to severe leuco-araiosis may be present.

Exclusion Criteria:

  • Secondary Normal pressure Hydrocephalus
  • Non-communicating hydrocephalus
  • Secondary NPH (after SAH, trauma, infection, neurosurgical procedure). Trauma or infection are regarded as relevant if the patient was unconscious in relation to the trauma or required hospitalisation for his meningo-encephalitis.
  • INPH-patients later shown to have ICP > 18 mm Hg.
  • Contra-indications to surgery.
  • Patients refusing shunt surgery
  • Restricted life-expectancy
  • Patients not capable of managing the tests or investigations at entry of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00874198

Locations
Germany
International Neuroscience Institute Hannover
Hannover, Lower Saxony, Germany, 30625
Sponsors and Collaborators
International Neuroscience Institute Hannover
Sahlgrenska University Hospital, Sweden
Department of Neurology and Neurosurgery,Westeinde Hospital, Den Haag
Uppsala University Hospital
University of Copenhagen
Unfallkrankenhaus Berlin
Saarland University
University of Padua
Masaryk University
Neurosurgical Department, University of Budapest, Hungary
Hospital Universitari de Bellvitge
Hospital General Universitario Gregorio Marañon
Neurosurgical Department, Clinique St. Jaen, Brussels, Belgium
Investigators
Principal Investigator: Petra M Klinge, MD International Neuroscience Institute Hannover
Principal Investigator: Carsten I Wikkelsoe, MD Sahlgrenska University, Gothenburg, Sweden
Principal Investigator: Jos TH Tans, MD Westeinde Hospital, Den Haag, Netherlands
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Prof. Dr. med. Petra M. Klinge, International Neuroscience Institute Hannover
ClinicalTrials.gov Identifier: NCT00874198     History of Changes
Other Study ID Numbers: european-nph-study-01, Dr.Klinge.C.T.Agreement08/2004, Dr.Klinge.C.T.Agreement10/2006
Study First Received: April 1, 2009
Last Updated: April 2, 2009
Health Authority: Germany: Ethics Commission
Germany: German Institute of Medical Documentation and Information

Keywords provided by International Neuroscience Institute Hannover:
normal pressure hydrocephalus
cerebrospinal fluid dynamic test
cerebrospinal fluid outflow resistance
cerebrospinal compliance
outcome
shunt surgery
normal pressure hydrocephalus guidelines
biomarkers
shunt surgery selection
Outcome measures
Outcomes assessment
Outcome and process assessment

Additional relevant MeSH terms:
Hydrocephalus
Hydrocephalus, Normal Pressure
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Intracranial Hypertension

ClinicalTrials.gov processed this record on September 18, 2014